Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06593197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients

StatusEnrolling by Invitation
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Sep 30, 2024 to Jan 1, 2025
    • Study sites: 0 to 1
    v3
  2. Start date: Sep 15, 2024 to Sep 30, 2024
    • Interventions: Apremilast (Drug) to Apremilast with NB-UVB (Combination Product), NB-UVB (Device)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department. It\'s an interventional study where Group A patient will be given NBUVB and Tab Apremilast 30 mg twice a day and Group B will receive NBUVB alone.
Trial Details
NCT Number NCT06593197
Lead Sponsor Dow University of Health Sciences
Conditions
(from sponsor)		 Vitiligo
Related terms Vitiligo
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov